Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Approval of an Amendment and Restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan
On January 25, 2023, the Board of Directors (the “Board”) of Gilead Sciences, Inc. (“Gilead”) approved an amendment and restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan (the “Purchase Plan”) and an amendment and restatement of the Gilead Sciences, Inc. International Employee Stock Purchase Plan (the “International Purchase Plan,” and together with the Purchase Plan, the “Plans”), subject to stockholder approval. A summary of the principal features of the Plans is set forth under Proposal 5 of Gilead’s definitive proxy statement filed with the Securities and Exchange Commission on March 23, 2023 (the “Proxy Statement”), which description is incorporated herein by reference.
The Plans were approved by Gilead’s stockholders at the 2023 Annual Meeting of Stockholders on May 3, 2023 (the “Annual Meeting”). The foregoing summary of the Plans does not purport to be complete and is qualified in its entirety by reference to the provisions of the Purchase Plan and the International Purchase Plan, which are attached to this Current Report on Form 8-K as Exhibit 10.1 and Exhibit 10.2, respectively, and are incorporated by reference herein. Item 5.07 Submission of Matters to a Vote of Security Holders.
The Annual Meeting was held on May 3, 2023. Of the 1,248,816,053 shares of the Company’s common stock entitled to vote at the Annual Meeting, 1,112,399,050 shares were represented at the meeting in person or by proxy, constituting a quorum. The voting results are presented below.
The Company’s stockholders elected nine directors to serve for the next year and until their successors are elected and qualified, or until their earlier death, resignation or removal. The votes regarding the election of directors were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Name | | Votes For | | Votes Against | | Abstentions | | Broker Non-Votes |
Jacqueline K. Barton, Ph.D. | | 986,415,013 | | | 13,491,911 | | | 2,001,479 | | | 110,490,647 | |
Jeffrey A. Bluestone, Ph.D. | | 995,919,933 | | | 3,943,946 | | | 2,044,524 | | | 110,490,647 | |
Sandra J. Horning, M.D. | | 981,121,155 | | | 18,770,573 | | | 2,016,675 | | | 110,490,647 | |
Kelly A. Kramer | | 966,965,833 | | | 32,909,136 | | | 2,033,434 | | | 110,490,647 | |
Kevin E. Lofton | | 925,933,861 | | | 73,885,649 | | | 2,088,893 | | | 110,490,647 | |
Harish Manwani | | 959,762,789 | | | 40,053,322 | | | 2,092,292 | | | 110,490,647 | |
Daniel P. O’Day | | 923,236,835 | | | 70,663,044 | | | 8,008,564 | | | 110,490,647 | |
Javier J. Rodriguez | | 993,470,838 | | | 6,361,800 | | | 2,075,765 | | | 110,490,647 | |
Anthony Welters | | 952,610,095 | | | 44,579,806 | | | 4,718,502 | | | 110,490,647 | |
The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal received the following votes:
| | | | | | | | |
Votes For | | 1,047,348,600 | |
Votes Against | | 63,802,874 | |
Abstentions | | 1,247,576 | |
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:
| | | | | | | | |
Votes For | | 919,145,382 | |
Votes Against | | 79,500,105 | |
Abstentions | | 3,262,916 | |
Broker Non-Votes | | 110,490,647 | |
The Company’s stockholders voted, on an advisory basis, on the frequency of future advisory stockholder votes on executive compensation. The frequency receiving the most votes was 1 Year. The proposal received the following votes:
| | | | | | | | |
1 Year | | 985,408,193 | |
2 Years | | 947,804 | |
3 Years | | 14,113,020 | |
Abstentions | | 1,439,386 | |
Broker Non-Votes | | 110,490,647 | |
In accordance with the Board’s recommendation as set forth in the Proxy Statement and consistent with the stated preference of the Company’s stockholders, the Company has determined that future advisory stockholder votes on executive compensation will be conducted on an annual basis, until the next advisory vote on this matter is held.
The Company’s stockholders approved an amendment and restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan. The proposal received the following votes:
| | | | | | | | |
Votes For | | 996,900,619 | |
Votes Against | | 3,074,231 | |
Abstentions | | 1,933,553 | |
Broker Non-Votes | | 110,490,647 | |
The Company’s stockholders did not approve a stockholder proposal requesting the Board implement a process to nominate at least one more candidate than the number of directors to be elected. The proposal received the following votes:
| | | | | | | | |
Votes For | | 7,422,311 | |
Votes Against | | 982,909,852 | |
Abstentions | | 11,576,240 | |
Broker Non-Votes | | 110,490,647 | |
The Company’s stockholders did not approve a stockholder proposal requesting the Board amend the company governing documents to give street name shares and non-street name shares an equal right to call a special stockholder meeting. The proposal received the following votes:
| | | | | | | | |
Votes For | | 46,426,089 | |
Votes Against | | 940,591,356 | |
Abstentions | | 14,890,958 | |
Broker Non-Votes | | 110,490,647 | |
The Company’s stockholders did not approve a stockholder proposal requesting a report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents. The proposal received the following votes:
| | | | | | | | |
Votes For | | 165,422,837 | |
Votes Against | | 824,383,326 | |
Abstentions | | 12,102,240 | |
Broker Non-Votes | | 110,490,647 | |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| | | | | | | | |
Exhibit Number | | Description |
| | |
| | |
104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document) |